Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Stock Screener   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in
 
Register now or login to post to this thread.
  • Page:
  • 1

Investor Evening - 20 February - Manchester - ANGLE, Cadence Minerals, First Sentinel, Plutus PowerGen & SkinBioTherapeutics     

Bullshare - 25 Jan 2018 14:24

The Sharesand AJ Bell Mediaevening event in Manchester is an opportunity for senior board directors from fast growing listed PLCs to make a presentation about their company and update existing & potential investors on their business plans for 2018.
 
During the event and afterwards over drinks, investors will have the chance to discover new investment opportunities and get to know the companies better by talking one on one with the company directors.
 

All attendees will be entered into free prize draws for:

Two pairs of tickets for Sale Sharks v Wasps on Sat 7th April at the AJ Bell Stadium, Eccles, Manchester M30 7WH      http://www.salesharks.com

Champagne afternoon tea for TWO at Cloud 23 on the 23rd floor of the legendary Beetham Tower in Deansgate, Manchester.  https://www.cloud23bar.com/

Evening Tasting Gift Experience at the Manchester Wine School. A gift voucher for TWO places on one of their evening tastings in Manchester City Centre. Gin, Champagne & Sparkling, Cheese or Food and Wine tasting/special event course of your choice. http://www.manchesterwineschool.com

The event will take place close to the City Centre at the Macdonald Manchester Hotel (London Road, Manchester M1 2PG) which is easily accessible by road, tram and rail.
 
 
Companies presenting:
 
ANGLE (AGL)  - ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market.  ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
 
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for;  Early detection of cancer; Personalised cancer treatment; Monitoring of cancer patients during treatment; and  Post-treatment monitoring of cancer patients in remission.
 
 
Cadence Minerals (KDNC) - Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
 
 
First Sentinel - First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.
 
This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.
 
First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. 
 
 
Plutus PowerGen(PPG) - Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver.
 
Plutus PowerGen has has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UK’s power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGen’s projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading ‘Big Six’ multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward.
 
 
PrimaryBid - PrimaryBid the leading online equity funding platform, available on both web and mobile, that enables investors to gain access to placings, fundraisings and IPOs of AIM-listed companies. The platform is open to all investors and is supported by the broking community as a way of accessing, on behalf of their AIM clients seeking capital, the large and active private investor market, as well as institutions.  To date almost £37m has been sourced for issuers, via the platform.
 
 
SkinBioTherapeutics (SBTX) - SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
 
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
 
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.
Who Should Attend?

The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.

Date:

Tuesday 20 February 2018

Venue:

Macdonald Manchester Hotel, London Road, Manchester, M1 2PG

Event Timings:
17.45 
Registration and coffee
18.15 
Presentations
• Andrew Newland, Chief Executive - ANGLE
• Kiran Morzaria, Director & CEO - Cadence Minerals (KDNC)
• Brian Stockbridge, CEO - First Sentinel
• Charles Tatnall, Executive Chairman - Plutus PowerGen
• Dave Mutton, COO - PrimaryBid
• Cath O'Neill, CEO - SkinBioTherapeutics
20.30 
Drinks reception and canapés
21.30 
Close
AJ Bell Youinvest
AJ Bell Youinvest 

AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Lifetime ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £1.50 and never costs more than £9.95 per online deal.

 

PrimaryBid
PrimaryBid 

PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges.  Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares.

Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment.  To date over £52m has been sourced via the platform.

ANGLE
ANGLE 

ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).

ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:

·         Early detection of cancer;

·         Personalised cancer treatment;

·         Monitoring of cancer patients during treatment; and

·         Post-treatment monitoring of cancer patients in remission.

Cadence Minerals (KDNC)
Cadence Minerals (KDNC) 

Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.

First Sentinel
First Sentinel 

First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.

This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.

First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).

 

Plutus PowerGen
Plutus PowerGen 
Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver.
 
Plutus PowerGen has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UK’s power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGen’s projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading ‘Big Six’ multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward.
 
 
SkinBioTherapeutics
SkinBioTherapeutics 

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.

Sponsored by:
AJ Bell Youinvest
Shares
PrimaryBid
  • Page:
  • 1
Register now or login to post to this thread.